LON:MXCT MaxCyte (MXCT) Share Price, News & Analysis GBX 1.17 -0.01 (-0.85%) As of 11/17/2026 Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsInsider TradesNews and Trends About MaxCyte Stock (LON:MXCT) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get MaxCyte alerts:Sign Up Key Stats Today's Range 1.16▼ 1.2650-Day Range 0.96▼ 1.7352-Week Range 147.69▼ 407.84Volume1.28 million shsAverage Volume42,065 shsMarket Capitalization£1.24 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview MaxCyte is a leading cell-engineering company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and to support innovative, cell-based research. MaxCyte brings best-in-class technology paired with ongoing support designed to facilitate complex engineering of a wide variety of cells and payloads, with the aim of advancing new treatment options for patients. For over 20 years, MaxCyte has been perfecting the art of cell-engineering, venturing beyond today’s process to innovate tomorrow’s solutions. Let’s Build Better Cells Together. To learn more, please visit www.maxcyte.com Read More Receive MXCT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MaxCyte and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MXCT Stock News HeadlinesMaxCyte Earnings Call Signals Growth Despite Akron CostsNovember 12, 2026 | tipranks.comMaxCyte falls after $151.8M deal to buy Akron Bio for cash and stockNovember 10, 2026 | msn.comI'm handing you this stock todayElon doesn't own the chip inside his Teslas or Starlink dishes. He licenses it from one little known public company. Now he's planning 1,000,000 AI satellites in orbit, and every one could pay this company a royalty. Analyst Dylan says the window to get in closes around December 8th, before new money floods into the buildout. | Behind the Markets (Ad)MaxCyte To Acquire AkronNovember 10, 2026 | rttnews.comMaxCyte (MXCT) Q3 2026: Revenue Surges 49% as Akron BioProducts Deal Reshapes the CompanyNovember 10, 2026 | 247wallst.comMaxCyte (LON:MXCT) Stock Price Down 5.8% - Time to Sell?November 10, 2026 | americanbankingnews.comMaxCyte stock surges 25% on raised 2026 revenue guidanceOctober 15, 2026 | au.finance.yahoo.comMaxCyte reiterates $30M-$32M 2026 revenue outlook as Genentech partnership expands enterprise modelAugust 13, 2026 | seekingalpha.comSee More Headlines MXCT Stock Analysis - Frequently Asked Questions How have MXCT shares performed this year? MaxCyte's stock was trading at GBX 1.58 at the beginning of the year. Since then, MXCT stock has decreased by 25.9% and is now trading at GBX 1.17. How do I buy shares of MaxCyte? Shares of MXCT stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of MaxCyte own? Based on aggregate information from My MarketBeat watchlists, some other companies that MaxCyte investors own include ARK Innovation ETF (ARKK), Caribou Biosciences (CRBU), Editas Medicine (EDIT), ImmunityBio (IBRX), Intellia Therapeutics (NTLA), Tesla (TSLA) and Walt Disney (DIS). Industry, Sector and Symbol Stock ExchangeLON SectorHealthcare Industry Life Sciences Tools & Services Sub-IndustryLife Sciences Tools & Services Current SymbolLON:MXCT CIKN/A Webwww.maxcyte.com Phone+1-301-9441700FaxN/AEmployees80Year FoundedN/AProfitability EPS (Trailing Twelve Months)GBX (40) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-£45.08 million Net Margins-106.29% Pretax MarginN/A Return on Equity-18.73% Return on Assets-11.07% Debt Debt-to-Equity Ratio8.74 Current Ratio10.88 Quick Ratio14.38 Sales & Book Value Annual Sales£32.29 million Price / Sales0.04 Cash FlowGBX 0.59 per share Price / Cash Flow1.97 Book ValueGBX 203.85 per share Price / Book0.01Miscellaneous Outstanding Shares106,319,000Free FloatN/AMarket Cap£1.24 million OptionableNot Optionable Beta1.13 The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (LON:MXCT) was last updated on 11/17/2026 by MarketBeat.com Staff. From Our PartnersYour $7 scanner is waitingThe Instant Scanner is $7 in Bill Poulos's Black Friday sale. Every night it delivers a list showing which sto...Profits Run | SponsoredPentagon magnet restrictions take effect January 1, 2027A NASDAQ-listed company has signed a term sheet outlining a potential 75-year agreement with the U.S. Army. It...OilPrice | SponsoredTop Trader Reveals Stunning Black Friday DealOthers paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Tradi...Base Camp Trading | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | Sponsored432 miles southeast of Washington, DC…Spruce Pine, North Carolina, a town of just over 2,000 people, has supplied a material to every major chip mak...Wall Street Watchdogs | SponsoredBeyond NVDA: The World’s Next #1 Company?This small-cap trades in an overlooked corner of the market, with a market cap more than 600X smaller than Nvi...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MaxCyte, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MaxCyte With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.